You are here

Alnylam

Biggest Winners in Biotech This Year

Motley Fool

Tue, 12/10/13 - 09:14 am

Puma Biotechnology

Celldex Therapeutics

Alnylam earns $7M payment for patisiran Phase II 'success'

The Fly on the Wall

Mon, 11/25/13 - 10:44 am

Alnylam rises as FDA bestows fast-track status

Yahoo/AP

Mon, 11/11/13 - 02:13 pm

Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial

Yahoo/BusinessWire

Sun, 11/10/13 - 01:08 pm

TTR-mediated amyloidosis

Alnylam 4Q loss widens on fewer drug partnerships

Yahoo/AP

Thu, 11/7/13 - 08:13 am

This New Cholesterol Treatment Has Blockbuster Potential

Motley Fool

Tue, 10/15/13 - 10:09 am

Alnylam advances Development Candidate for ALN-AS1

Yahoo/Fly on the Wall

Tue, 10/8/13 - 08:43 am

hepatic porphyrias

New Type of Drug to Lower LDL Looks Promising

Med Page Today

Thu, 10/3/13 - 11:33 am

LDL cholesterol

PCSK9 inhibitors

Alnylam's Biggest Opportunities

Motley Fool

Wed, 10/2/13 - 10:02 am

3 Promising Stocks Targeting CTGF and Dermal Scarring

Wall St Cheat Sheet

Sat, 09/14/13 - 10:56 am

dermal scarring

RXi Pharmaceuticals

Alnylam Targets New Highs On Data Supporting RNAi

Seeking Alpha

Sat, 07/20/13 - 11:18 am

RNA interference

This Week in Biotech

Motley Fool

Sun, 07/14/13 - 11:19 am

3 Humongous Health-Care Stocks This Week

Motley Fool

Sat, 07/13/13 - 11:46 am

Alnylam Soars To New High On Early Drug Trial Results

Investors.com

Fri, 07/12/13 - 07:32 am

Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Yahoo/BusinessWire

Sun, 06/30/13 - 10:42 am

TTR-mediated amyloidosis

Alnylam announces proof-of-concept data from RNAi program

Yahoo/Fly on the Wall

Fri, 05/17/13 - 11:28 am

Alnylam takes smaller 1Q loss on lower costs

Yahoo/AP

Tue, 05/7/13 - 11:41 am

Pages